Kornimate/medical-research-clean huggingface dataset:
analgesic efficacy of adding scb with low concentration bupivacaine combined with dexamethasone on pain after tka

Conditions: Total Knee Arthroplasty; Adductor Canal Block; Sciatic Nerve Block

Summary: this study evaluate the efficacy of adding popliteal sciatic nerve block with low concentration bupivacaine and dexamethasone to abductor canal block for total knee arthroplasty in patient with nsaids prescribing precaution. half of participants will receive popliteal sciatic nerve block, abductor canal block and periarticular injection, while the other half will receive a sham block, abductor canal block and periarticular injection.

after informed and consent, all patients will be devided into two groups, sciatic group (group s) and controlled group (group c). all patients will receive adductor canal block, then patients in group s will receive sciatic nerve block with low concentration bupivacaine and dexamethasone while partients in group c will receive sham block. all patient will receive spinal anesthesia and intraoperative periarticular injection. postoperative pain score, muscle strength, total morphine consumption and adverse events will be record in case record form.

Eligibility criteria:
inclusion criteria: * patient scheduled for single total knee arthroplasty * patient with nsaids prescribing precautions such as history of nsaids allergy, chronic kidney disease (gfr\< 50 ml/min), history of ischemic heart disease or cerebrovascular disease exclusion criteria: * patient refusal * body weight less than 45 kg * history of allergy to bupivacaine or dexamethasone * uncontrolled diabetes mellitus * contraindicated for spinal block, adductor canal block or sciatic nerve block * inability to assess pain score (cognitive or psychiatric history) * patient scheduled for revision tka * preexisting neuropathy or neurological deficit in lower extremity * preexisting chronic pain (prolonged use of oral morphine 20 mg/day or equivalent)

Keywords: popliteal sciatic nerve block total knee artgroplasty adductor canal block dexamethasone
function and scoliosis surgery

Conditions: Adolescent Idiopathic Scoliosis

Summary: the purpose of the study is to examine the changes in function and performance biomechanics in patients undergoing spinal fusion corrective surgery for adolescent idiopathic scoliosis (ais).

methods will consist of movement studies, questionnaires, and chart review. the recruited subjects will be followed at the usual clinical schedule of pre-op, 6-week, 3 -, 6- and 12-month post-operative follow-up visits. after signing informed consent, age at time of surgery, height, weight, body composition, leg length will be recorded to be used during data processing. chart review will further yield data on cobb angle, lenke scoliosis classification, instrumentation used during surgery, and level of spinal fusion. all subjects will be asked to complete assessments of activity level (marx score, tegner activity score), general health (eq-5d), and a validated scoliosis survey (scoliosis research study questionnaire srs-22). movement studies will consist of the lower quarter y balance test (ybt-lq), and functional movement screen (fms), and measures of forward flexion, right and left lateral bending, and right and left trunk rotation. these measures will be assessed preoperatively and at postoperative follow-up visits.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic scoliosis * patients identified to undergo spinal fusion surgery * treated at duke university medical center exclusion criteria: * neuromuscular or congenital scoliosis

Keywords: adolescent idiopathic scoliosis functional movement screen y balance test
internet-delivered attention training for obsessive-compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: the goal of this study is to investigate an attention training program for participants with obsessive-compulsive disorder. the attention training consists of a modified dot probe task with picture stimuli related to washing and checking paired with neutral pictures. participants are randomly assigned to an experimental and a placebo-control group. after a minimum of 4 weeks of attention training we expect to find differences between participants of the experimental and the control group in terms of attention bias, ocd symptoms, anxiety and depression.


Eligibility criteria:
inclusion criteria: * diagnosis of primary ocd according to oci-r self report (cut-off \>=18) exclusion criteria: * suicidal * substance abuse or addiction * psychotic symptoms * visual impairment if not compensated with optical aid current treatment is not an exclusion criterion, but data on treatment status (current psycho- or pharmacotherapy for ocd) will enter our statistical analyses.

Keywords: obsessive-compulsive disorder attention training attention bias modification dot-probe task randomized controlled trial online treatment washing checking
real-life management and therapeutic outcome of patients with chronic rhinitis and chronic urticaria in thailand

Conditions: Allergic Rhinitis; Non-allergic Rhinitis; Chronic Urticaria

Summary: observation study of patients with chronic rhinitis or chronic urticaria in thailand

all patients presenting with symptoms of chronic rhinitis for at least 12 consecutive or non-consecutive weeks per years or symptoms of chronic urticaria for at least 6 weeks will be asked to complete the case report forms asking for details of symptom characteristics, risk factors, personal habits, underlying diseases, and quality of life at the first visit. investigation results, final diagnosis, and therapeutic interventions will also be recorded by the responsible allergist. on every follow-up appointment, patient symptoms, aggravating factors, medication use and side effects will be completed by patients. new findings, associated diseases, and prescriptions will be completed by allergist. the unfilled variables by patients will be asked in the following visit. any "non-reported" variables those are unable to retrieve will be treated as missing data for data analysis. the estimated sample size is about 200 new cases per year. patient demographic data, clinical presentations, and associated diseases will be reported. the association between clinical characteristics and quality of life will be analyzed. the relationship between clinical manifestations and therapeutic outcomes will be determined.

Eligibility criteria:
inclusion criteria: * have symptoms of chronic rhinitis for at least 12 consecutive or non-consecutive weeks per year or symptoms of chronic urticaria for at least 6 weeks exclusion criteria: * less than 15 years of age

Keywords: allergic rhinitis non-allergic rhinitis chronic urticaria
study for the assessment of the quality of echocardiographic clips.

Conditions: Cardiac Disease

Summary: this study main objective is to evaluate the safety and efficacy of the ultrasight ai guidance software. the investigational product is a software that guides the user to capture a high quality ultrasound image. the study will include healthcare professionals, not specialized in echocardiography, who will perform echocardiography by using ultrasight ai guidance software, on subjects in the medical centers cardiac units.

this pivotal study is a multi-center, multi-reader multi-case (mrmc) study, designed to assess the quality of the clips obtained by novice users when using the ultrasight ai guidance software. prior to the study start, there will be a pre-study training phase for training the novice users. during the study, eligible subject will undergo the echocardiography examination twice on a single study visit (same day): once by one of the novice users when using the ultrasight ai guidance software, and once by an expert sonographer without the aid of the software. each novice user will perform the examination on at least 20 subjects (with the aim that the number of examinations by each novice will be similar). all examinations will be sent to multiple board certified cardiologists for their quality evaluations.

Eligibility criteria:
inclusion criteria: 1. age 18 and older 2. subjects willing and able to give written informed consent. exclusion criteria: 1. emergency (non-elective) admission within 24 h prior to participating in the study 2. female subjects who are pregnant (women of childbearing potential will perform a urine pregnancy test) 3. unable to lie as required in all the classic positions for standard tte exam: supine on back / left decubitus 4. subjects who currently participate a clinical trial, involving interventional cardiac devices. 5. subjects who have prior echo exam with description of low/poor quality exam in the echo report 6. subjects with bmi above 40 7. subjects experiencing a known or suspected acute cardiac event 8. subjects with severe chest wall deformity as per previous medical records and physical examination 9. subjects who have undergone pneumonectomy 10. subjects whose anatomy does not lend itself to yield diagnosable standard echocardiography clips (i.e. situs inversus with dextrocardia, single ventricle anatomy due to congenital heart disease, etc.). * a woman is of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., müllerian agenesis.).
dose dense rituximab for high risk newly diagnosed acute immune thrombocytopenic purpura

Conditions: Immune Thrombocytopenic Purpura

Summary: the purpose of this study is to determine if a dose dense administration of rituximab in newly diagnosed acute immune thrombocytopenic purpura (itp) and determine relapse rate following this treatment. correlative studies will be performed as outlined in the appendices. quality of life will be measured using the kit as outlined in the protocol.


Eligibility criteria:
inclusion criteria: * age: subjects must be ≥ 1 year and ≤ 21 years of age. * diagnosis: patients must have newly diagnosed itp and a platelet count of ≤ 20 x 109 per liter. bone marrow aspirate and biopsy should be performed to rule out malignancy in the bone marrow. * high-risk features : in addition, patients must have one of more of the following high-risk criteria: * age ≥ 10 years * grade ii-iv bleeding at diagnosis * ana positivity * no history of preceding infection within 2 weeks prior to itp diagnosis * performance status: patients must have a performance status ≥ 50%. use karnofsky for patients \> 16 years of age and lansky for patients less than or equal to 16 years of age. see appendix i for performance score. * prior therapy * patients may not have received any treatment for itp prior to start of therapy. * patients may not receive systemic steroids ≥ 0.5 mg/kg prednisone (or equivalent) within 2 weeks prior to diagnosis. * concomitant medications restrictions: * steroids are only warranted as premedication prior to rituximab. * patients who receive thrombopoetic agonists, eltrombopag or romiplostim will be taken off protocol. * organ function requirements * adequate renal function defined as: estimated crcl \> 60 ml/min or \>30% of gfr for age based on the schwartz formula * adequate liver function defined as: ast and/or alt less than 5 times the upper limit of normal, and/or direct bilirubin less than the 2 times of the upper limit of normal exclusion criteria * patients with a history of grade iii-iv allergic reaction to rituximab * patients with bone marrow neoplastic infiltration * patients with a history of hepatitis b infection * pregnancy and breast feeding * female patients who are pregnant are ineligible (insert the reason: "due to risks of fetal and teratogenic adverse events as seen in animal/human studies" or "since there is yet no available information regarding human fetal or teratogenic toxicities"). * lactating females are not eligible unless they have agreed not to breastfeed their infants. * female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
obese patients with type 2 diabetes

Conditions: Obesity; Diabetes Mellitus, Non-Insulin-Dependent; Obesity in Diabetes

Summary: to assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with type 2 diabetes


Eligibility criteria:
* bmi must be greater than 27 and less than 40 * treated type 2 diabetes on single therapy treatment for at least 1 year * stable weight (variation of less than 5 kg within 3 months prior to screening visit)

Keywords: diabetes obesity
phase ii trial of sbrt + or - imrt in treatment of patients with clinically confined prostate adenocarcinoma

Conditions: Prostate Adenocarcinoma

Summary: patients with locally confined prostate adenocarcinoma (clinical stage t1c - t2bn0m0, gleason score 7, psa 20 ng/ml) are assigned to one of two treatment arms. low risk patients (t1c-t2a and psa \ 10 ng/ml orgleason score 7) will receive 1.8 gy of imrt for 25 fractions over 5 weeks for a total of 45 gy. they will then receive a boost consisting of 4, 5.5 gy fractions after imrt for a total of 22 gy.

patients with locally confined prostate adenocarcinoma (clinical stage t1c - t2bn0m0, gleason score 7, psa 20 ng/ml) are assigned to one of two treatment arms. low risk patients (t1c-t2a and psa \ 10 ng/ml orgleason score 7) will receive 1.8 gy of imrt for 25 fractions over 5 weeks for a total of 45 gy. they will then receive a boost consisting of 4, 5.5 gy fractions after imrt for a total of 22 gy. all patients will be assessed for toxicity at periodic time points following completion of treatment.

Eligibility criteria:
inclusion criteria: * histologically determined adenocarcinoma is required. * all other histologies are excluded. * tissue for diagnosis must be obtained by transrectal ultrasound biopsy. * gleason scoring classification of the biopsy specimen is required and must be greater than or equal to 7. * 2002 ajcc clinical cancer stage as determined by either urologist or radiation oncologist must be t1c - t2b, n0, m0. * n0 stage may be assigned following either negative imaging or negative pathologic assessment. * prostate volume as assessed by trus must be less than 60 cc. 3.1.5. * psa must be less than 20 ng/ml. , * age ≥ 18, * ipss voiding symptoms score must be less than 18, * study consent form must be signed by the patient. exclusion criteria: * gleason score of 8 - 10, * clinical stage t3 - t4, * age ≤ 18, * any evidence of nodal (n1) or distant (m1) disease, * prostate volume as assessed by trus \> 60 cc, * psa \> 20 ng/ml, * ipss voiding symptoms score \> 18, * prior turp, * prior pelvic radiotherapy or chemotherapy, * prior prostatectomy, * prior cancer other than basal cell or squamous cell skin carcinoma unless free of disease for \> 5 years, * current medical or psychiatric illness that may interfere with treatment completion and followup, * hip prosthesis, * unable or unwilling to give informed consent

Keywords: locally confined
effects of covid-19 on the elderly

Conditions: Pain; Fear; Falling; Physical Activity; COVID-19; Aged

Summary: the goal of this observational study is to learn about in former covid-19 patients. the main questions it aims to answer are: * are there any association among pain, fear of falling, fall frequency, and physical activity level * are there any difference between former covid-19 elders and non-covid-19 elderly population


Eligibility criteria:
inclusion criteria: * being 65 years or older * being cooperative exclusion criteria: * refusing to participate in the study * having significant vision and hearing problems * not completing the study questions

Keywords: covid-19 pain fear falling physical activity aged
rct of the cutting balloon versus a high pressure balloon for the treatment of arteriovenous fistula stenoses

Conditions: Stenosis

Summary: the proposed study will investigate the efficacy of the peripheral cutting balloon (pbc) compared to the high pressure balloon in dilating venous stenosis in hemodialysis fistulas. 2. specific aims study endpoints will be: primary endpoint 1. primary and assisted patency at 6 months secondary endpoints: 1. procedure effectiveness/residual stenosis 2. procedure-related complications 3. primary patency and primary assisted patency 12 months 4. secondary patency at 6 and 12 months 5. number/type of secondary interventions.


Eligibility criteria:
inclusion criteria: * dysfunctional fistulas will be recruited based on the presence of clinical and hemodialysis parameters exclusion criteria: * arteriovenous prosthetic grafts

Keywords: balloon angioplasty autogenous fistula
a study of ganfort® ud in patients with primary open angle glaucoma (poag) or ocular hypertension (oht) in a medical setting

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Summary: the study will evaluate patients diagnosed with poag or oht who are switched to ganfort® ud (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical practice. all treatment decisions lie with the physician.


Eligibility criteria:
inclusion criteria: * diagnosed with primary open-angle glaucoma or ocular hypertension * previously prescribed intraocular pressure (iop)-lowering medication with insufficient iop control and is now being switched to ganfort® ud for medical reasons exclusion criteria: * none
urine ph as a predictor of diabetes

Conditions: Diabetes

Summary: urine ph has been lately linked to insulin resistance. the early phase of diabetes mellitus involves insulin resistance. thus, the investigators want to check if a simple cheap study like a urine analysis that can predict diabetes.


Eligibility criteria:
inclusion criteria: * age \> 18 exclusion criteria: * diabetes * ckd * urine infection * uto * bladder dysfunction

Keywords: diabetes urine ph insulin resistance metabolic syndrome development of diabetes
treatment of hcv-infected recent injection drug users in u.s. liver clinics

Conditions: Chronic Hepatitis C; People Who Inject Drugs

Summary: direct antiviral therapy (standard of care) administered to chronic hepatitis c-infected patients, in two hepatology clinics, who had used intravenous drugs in the past 6 months of signing informed consent (ic). this cohort was compared to concurrently treated chronic hepatitis c patients who were not intravenous drug users, who signed ic in these same clinics. follow-up expected two years after cure and relapse rates recorded. primary end point was svr rate and secondary end points included reinfection rates in follow-up period.

chronically hcv-infected participants were recruited and treated at two liver referral clinics in georgia, but had been referred from opioid substitution therapy clinics, primary care and gi clinics, neighboring hospitals, and correctional centers. once consented, a nurse navigator was assigned to each participant was responsible for all subjects' appointments, and med supplies. drug testing was mandated at specified intervals. patients with recent injection drug use (within 6 months) were assigned to the pwid (people who inject drugs) arm, and those who hadn't injected within 6 months, but agreed to be in the study and signed consents, were assigned to the non-pwid arm. both groups were treated with velpatasvir (100 mg) and sofosbuvir (400 mg) once daily for 12 weeks (brand or branded generic). adherence was assessed by pill counts. mandatory treatment visits were scheduled for baseline, 4 and 12 weeks (+/- 2 weeks) and follow-up (fu) week 12 (+ 4 months). long-term fu was flexible and could be virtual, but was mandated once yearly with hcv rna testing.

Eligibility criteria:
inclusion criteria: * chronic hcv infection and pwid arm: use of intravenous drug use at least once in preceding six months. in non-pwid arm: no use of intravenous drug use at least once in preceding six months. exclusion criteria: * co-infection with chronic hepatitis b; decompensated cirrhosis current or by history; inability to sign informed consent; unwilling to take therapy or unable to obtain therapy
ullevål personalityproject

Conditions: Personality Disorders

Summary: ullevål personalityproject is a ranomized controlled trial of treatment of patients with personality disorder. it's main purpose is to test the effect of a long-term combined treatment program compared with eclectic individual therapy for patients with personality disorders. the main study hypothesis is that long-term combined treatment is superior to eclectic individual therapy with respect to improvement in personality functioning, psychosocial functioning, symptoms, interpersonal problems, and self destructive behavior for poorly functioning patients with personality disorders.

ullevål personalityproject is a ranomized controlled trial of treatment of patients with personality disorder. it's main purpose is to test the effect of a long-term combined treatment program compared with eclectic individual therapy for poorly functioning patients with personality disorders. the experiment treatment is guided by written treatment guidelines and comprises: 1. 18 weeks intensive day treatment 2. followed by long-term outpatient combined group psychotherapy and individual therapy for 4 and 2,5 years respectively. the control treatment comprises: 1. eclectic psychotherapy, here understood as psychotherapy according to the preference and regular practice of the therapist. 120 patients with personality disorders admitted to department of personality psychiatry, psychiatric division, ullevål university hospital are randomized to either experiment or control condition. the patients are evaluated at baseline and after 8, 18, 36, 72 months. the evaluations comprise a large battery of psychological tests and structured interviews.

Eligibility criteria:
inclusion criteria: * patients with personality disorders admitted to department for personality psychiatry, psychiatric division, ullevål university hospital exclusion criteria: * schizotypal personality disorder, antisocial personaliy disorder, current alcohol or drug dependence, developmental disorders (e.g. asperger), symptoms due to organic conditions, and lack of a permanent residence.

Keywords: personality disorders, day treatment, group psychotherapy, combined psychotherapy, outcome, attachment pattern